Skip to main content
. 2015 Aug 11;11(9):1594–1607. doi: 10.1080/15548627.2015.1068489

Figure 8.

Figure 8.

Inhibitors of v-ATPase are the most potent activators of MTORC1 in chondrocytes. (A) MEFs and C5.18 chondrocytes were treated with varying doses of concanamycin for 48 h. (B) C5.18 chondrocytes were treated with varying doses of Baf, 3-MA, CQ and leupeptin for 48 h. In all panels the levels of p-RPS6 and SQSTM1 were analyzed by western blot.